Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DOTA-PTR-58
- Development stage
- Unknown
- Lead developer
- Starget Pharma
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
DOTA-PTR-58 is a first-in-class superagonist radioligand developed by Starget Pharma, specifically designed to target somatostatin receptor type 3 (SSTR-3) with sub-nanomolar affinity. The agent is a theranostic radiopharmaceutical consisting of a DOTA-conjugated backbone cyclic peptide (PTR-58) that can be labeled with either Gallium-68 (Ga-68) for diagnostic PET imaging or Lutetium-177 (Lu-177) for targeted radionuclide therapy. By binding to SSTR-3, which is overexpressed in various malignancies including soft-tissue sarcomas, neuroendocrine tumors (NET), melanoma, and hepatocellular carcinoma, DOTA-PTR-58 delivers a concentrated radioactive payload directly to cancer cells. It is currently undergoing Phase 1b clinical evaluation to assess its safety and efficacy in patients with SSTR-3-positive tumors.
- Other names
- PTR-58PTR58PTR 5868Ga-DOTA-PTR-58177Lu-DOTA-PTR-58
02
Targets
SSTR3 (Somatostatin receptor 3)
Beyond the preview
Go deeper on DOTA-PTR-58.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DOTA-PTR-58.